期刊文献+

一例重症胰腺炎伴多药耐药肺炎克雷伯菌脓毒血症治疗成功的抗感染策略分析 被引量:2

The therapeutic strategy in the successful treatment of a patient with severe pancreatitis combined with multiple drug resistant Klebsiella pneumoniae sepsis
下载PDF
导出
摘要 目的:讨论一例重症胰腺炎伴发多药耐药(MDR)肺炎克雷伯菌(Kpn)脓毒血症治疗成功的抗感染策略,为MDR-Kpn的治疗积累经验。方法:记录病人的临床表现,结合各项实验室检验指标及抗感染治疗药物种类、疗程及联用方案,分析抗菌药物治疗策略。结果:该例病人住院期间依次使用了替加环素+亚胺培南/西司他汀钠、替加环素+亚胺培南/西司他汀钠+阿米卡星、替加环素+头孢哌酮钠/舒巴坦钠、头孢哌酮钠/舒巴坦钠+阿米卡星、头孢哌酮钠/舒巴坦钠+磷霉素的多药联合治疗方案。入院第52天血培养转阴并保持,各项细菌感染炎性指标转为正常,病情好转稳定,MDR-Kpn脓毒血症治愈。结论:MDR-Kpn在缺乏明确有效的抗菌药物时,及时联合应用治疗Kpn的一线和二线药物,延长疗程是治疗成功的关键。 Objective: To discuss the anti-infection strategy for the successful treatment of a case of severe pancreatitis combined with multiple drug resistant Klebsiella pneumoniae (MDR-Kpn) sepsis and to accumulate clinical experience for the treatment of MDR-Kpn. Methods:Anti-bacterial drug treatment strategy was analyzed through recording of clinical manifesta- tions associated with various biochemical indicators and categories of anti-infectious drugs, treatment courses and drug combina- tion profiles. Results:During hospitalization, the patient was treated in sequence with various combinations of antibiotics, inclu- ding tigecycline plus imipenem/eilastatin sodium, tigeeyeline plus imipenem/cilastatin sodium plus amikacin, tigecycline plus eef operazone sodium/sulbaetam sodium, cefoperazone sodium/sulbactam sodium plus amikaein,and eefoperazone sodium/sulbactam sodium plus fosfomycin. Fifty-two days after admission into the hospital, blood culture turned negative and was stably main- tained. All the inflammatory markers returned to normal. The patient's conditions became stable, and finally this rare case of MDR-Kpn sepsis was cured successfully. Conclusion: Without definitively effective anti-bacterials, in-time combined therapy with first-line and second-line drugs and with extended treatment courses was the key to the successful treatment of MDR-Kpn sepsis.
出处 《药学服务与研究》 CAS 2015年第5期329-333,共5页 Pharmaceutical Care and Research
关键词 肺炎克雷伯菌 多药耐药 联合用药 重症胰腺炎 脓毒血症 Klebsiella pneumonia multiple drug resistance combined medication severe pancreatitis sepsis
  • 相关文献

参考文献15

  • 1Munoz-Price L S,Poirel L,Bonomo R A,et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases[J]. Lancet Infect Dis,2013,13(9):785-796.
  • 2Lee G C,Burgess D S. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections:a review of published case series and case reports[J]. Ann Clin Microbiol Antimicrob,2012,11:32.
  • 3Magiorakos A P,Srinivasan A,Carey R B,et al. Multidrug-resistant,extensively drug-resistant and pandrug-resistant bacteria:an international expert proposal for interim standard definitions for acquired resistance[J]. Clin Microbiol Infect,2012,18(3):268-281.
  • 4Petrosillo N,Giannella M,Lewis R,et al. Treatment of carbapenem-resistant Klebsiella pneumoniae:the state of the art[J]. Expert Rev Anti Infect Ther,2013,11(2):159-177.
  • 5管婧,卓超,苏丹虹,倪语星,孙景勇,汪复,朱德妹,胡付品,徐英春,张小江,俞云松,杨青,陈中举,孙自镛,张朝霞,季萍,单斌,杜艳,张泓,孔菁,徐元宏,沈继录,王传清,王爱敏,胡志东,李全,魏莲花,吴玲,胡云建,艾效曼.2012年中国CHINET克雷伯菌属细菌耐药性监测[J].中国感染与化疗杂志,2014,14(5):398-404. 被引量:31
  • 6朱健铭,姜如金,孔海深,张嵘,吕火祥,孙长贵,黄支密.多重耐药肺炎克雷伯菌发现一组gyrA、parC、qnrS基因新变异型[J].中华流行病学杂志,2013,34(1):61-66. 被引量:13
  • 7朱德妹,汪复,胡付品,蒋晓飞,倪语星,孙景勇,徐英春,张小江,胡云健,艾效曼,俞云松,杨青,孙自镛,陈中举,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,王爱敏,张泓,孔菁,徐元宏,沈继录,单斌,杜艳.2010年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2011,11(5):321-329. 被引量:651
  • 8van Duin D,Kaye K S,Neuner E A,et al. Carbapenem-resistant Enterobacteriaceae:a review of treatment and outcomes[J]. Diagn Microbiol Infect Dis,2013,75(2):115-120.
  • 9王淑洁,王育琴,张海林.《抗菌药物临床应用指导原则》依从性研究[J].中国药房,2008,19(8):635-637. 被引量:40
  • 10Tzouvelekis L S,Markogiannakis A,Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae:an evolving crisis of global dimensions[J]. Clin Microbiol Rev,2012,25(4):682-707.

二级参考文献44

  • 1朱健铭,姜如金,吴康乐,马兆龙,孔海深,张嵘,吕火祥,黄支密,孙长贵.肺炎克雷伯菌临床分离株β-内酰胺类耐药特征分析[J].中华临床感染病杂志,2011,4(5). 被引量:20
  • 2王明贵.喹诺酮类抗菌药的耐药性及质粒介导耐药机制[J].中华医学杂志,2006,86(9):645-647. 被引量:35
  • 3Arias CA,Murray BE.Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J].N Engl J Med,2009,360(5):439-443.
  • 4Clinical and Laboratory Standads Institute.Performance Standards for Antimicrobial Susceptibility Testing[S].Fifteenth Informational Supplement,2010,M100-S20 Vol 30 No.1.
  • 5Clinical and Laboratory Standads Institute Performance Standards for Antimicrobial Susceptibility Testing[S].Fifteenth Informational Supplement,2010,M100-S20-U Vol 30 No 15.
  • 6Clinical Laboratory Standard Institute.Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria[S].Approved Guideline M45-A,Vol.26 No.19,2006.
  • 7Wang P,Hu FP,Xiong ZZ,et al.Susceptibility of ESBL-Producing nterobacteriaceae with the New CLSI Breakpoints[J].J Clin Microbiol,2011,49(6):3127-3131.
  • 8Yang Q,Wang H,Sun H,et al.Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems:results from large hospital-based surveillance studies in China[J].Antimicrob Agents Chemother,2010,54(1):573-577.
  • 9Wang H.Guo P,Sun HL,et al.Molecular epidemiology of clinical isolates of carbapenem-resistant Acinerobacter spp from Chinese hospitals[J].Antimicrob Agents Chemother.2007,51(11):4022-4028.
  • 10卫生部,国家中医药管理局,总后卫生部.抗茵药物临床应用指导原则[S].卫医发[2004]285号.

共引文献729

同被引文献16

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部